PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon *

Learn more about the emerging evidence of PROTAC ER degraders to treat estrogen receptor–positive/HER2-negative metastatic breast cancer, including mechanisms of action and how these novel therapies compare to standard-of-care endocrine therapies. 

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Pfizer Inc. and Arvinas.

Arvinas

Pfizer Inc.

*PCE is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.